P2Y12 Receptor Inhibitors in Non-ST-Segment Elevation Acute Coronary Syndrome Patients: An Assessment of Current Evidence

The European Heart Association’s guideline update on NSTE-ACS management in 2020 took into consideration several landmark trials, which ultimately changed the level of recommendation on key aspects of antiplatelet use, in both pre- and post-PCI practice. This roundtable, led by Prof Dominick Angiolillo, considers the main updates, the data underpinning the changes and what they mean for real-world practice through expert discourse and case examination.

Target Audience

This programme is intended to educate:

  • Heart Failure Specialists
  • General Cardiologists
  • Nurses
  • Allied Health Professionals

Learning Objectives

  1. Recall the supportive evidence underpinning recommended antiplatelet approaches in individuals with unknown coronary anatomy, including choice of therapy, duration, timing and loading doses
  2. Compare the design of different clinical trials that have influenced antiplatelet therapy choice in NSTE-ACS patients who proceed to PCI 
  3. Apply trial data and clinical guidelines on the use of antiplatelet therapy in patients undergoing revascularisation to a surrogate patient case

     

R-CME DISCLAIMER / TERMS & CONDITIONS

In compliance with EBAC / EACCME guidelines, all speakers/chairpersons participating in this programme have disclosed or indicated potential conflicts of interest which might cause a bias in the presentations. The Organising Committee/Course Director is responsible for ensuring that all potential conflicts of interest relevant to the event are declared to the audience prior to the CME activities.

Intended for healthcare professionals only. This IME programme is supported by an unrestricted educational grant from AstraZeneca, who has had no involvement in its organisation. Views and opinions expressed in the programme belong to the authors (faculty and delegates) and not necessarily to that of AstraZeneca.

Radcliffe Education requires contributors to our CME programmes to disclose any relevant financial relationships that have occurred within the past 12 months that could create a conflict of interest. These will be identified in the faculty section if applicable.
 

INSTRUCTIONS TO PARTICIPANTS

There is no fee for taking part in this online learning activity.

Activities are designed to be completed within 60 minutes and must be completed by the registered user. Physicians should only claim credits for time spent on the activity. To successfully earn credit, participants must complete the activity in full in the indicated time frame.

To complete the course and claim certification participants must:

  • Read the course outline information supplied and complete pre-test questions if supplied prior to starting the activity. Users must read and study the activity in its entirety before completing the post-test questions.
  • Your results will be automatically saved and if a pass score is achieved (where applicable), you may be eligible to claim credit for the activity and receive a certificate of completion.
Course summary
Available credit: 
  • 1.00 European Board for Accreditation in Cardiology (EBAC)
Course opens: 
05/06/2021
Course expires: 
07/05/2022
Cost:
£0.00
Rating: 
0

Part 1 - Guideline updates: A brief review of changes to the ESC 2020 guideline updates in NSTE-ACS in both the pre-intervention and post-PCI setting.

Part 2 - Overview of clinical trials for patients undergoing intervention:
a. PLATO
b. TRITON-TIMI 38
c. ACCOAST
d. SCAAR
e. ISAR-REACT 5

Part 3 - Deep dive into trial design: This session is designed to take a subjective view of the most recent changes in the ESC guidelines and to assess the trials and their design

Part 4 - Example patient case: Patient of unknown coronary anatomy presenting for PCI.

Part 5 - Audience Q&A

  • Prof Dominic Angiolillo, University of Florida College of Medicine, Jacksonville, USA
  • Dr Roxana Mehran, Mount Sinai Hospital, New York, NY, USA
  • Prof Gilles Montalescot, Centre Hospitalier Universitaire Pitié-Salpêtrière, Paris, France
  • Prof Rob Storey, University of Sheffield, UK

The programme ‘P2Y12 Receptor Inhibitors in Non-ST-Segment Elevation Acute Coronary Syndrome Patients: An Assessment of Current Evidence’ is accredited by the European Board for Accreditation in Cardiology (EBAC) for 1 hour of external CME credits.

Each participant should claim only those hours of credit that have actually been spent in the educational activity. EBAC works according to the quality standards of the European Accreditation Council for Continuing Medical Education (EACCME), which is an institution of the European Union of Medical Specialists (UEMS).

Through an agreement between the European Board for Accreditation in Cardiology and the American Medical Association, physicians may convert EBAC External CME credits to AMA PRA Category 1 Credits™. Information on the process to convert EBAC credit to AMA credit can be found on the AMA website.

Available Credit

  • 1.00 European Board for Accreditation in Cardiology (EBAC)

Price

Cost:
£0.00
Please login or register to take this course.